Of note, the PI3K inhibitors alpelisib, in combination with fulvestrant [9, 10], and inavolisib, in combination with palbociclib and fulvestrant [10], are indicated for certain patients with HR-positive/HER2-negative advanced breast cancer with tumors harboring PIK3CA-activating mutations. The gene discussed is ERBB2; the disease is breast carcinoma.